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Objective: We sought to determine the variables influencing long-term survival of
patients treated for bronchial carcinoid tumors.
Methods: A retrospective, mono-institutional review of patients subjected to surgi-
cal treatment since 1977 was conducted.
Results: Over 22 years, 126 patients with a final histologic diagnosis of bronchial
carcinoid tumors were assessed for surgery. The group comprised 72 men (57%)
and 54 women (43%) with a mean age at presentation of 47 ± 16 years (range 11-
77 years). Symptoms were present in 65 (53%) patients. Operations included lobec-
tomy or bilobectomy in 88 (with 4 bronchoplastic procedures), pneumonectomy in
15, segmentectomy in 3, wedge resection in 16, and bronchial sleeve resection in 3
patients. One patient (0.7%) died in the perioperative period. Eighty-two patients
(65%) had typical and 44 (35%) had atypical carcinoid tumors. Postoperative stag-
ing was complete for 113 of 126 patients (13 patients did not undergo lym-
phadenectomy): 90 patients had stage I disease, 6 had stage II, 15 had stage III, and
2 had stage IV disease. A typical subtype was stage I in 70 and more advanced (II-
IV) in 5, whereas an atypical subtype was stage I in 20 and more advanced in 18 (P
< .05). Mean follow-up was 99 ± 73 months (range 6-282 months) during which 19
(15%) patients died (12 of recurrent disease). Recurrent tumor developed in 4
(5.5%) of 72 patients affected by typical subtypes and 8 (19.5%) of 41 by atypical
subtypes with complete follow-up. Overall survival at 15 years was 74%; survival
related to histologic type and nodal status at 15 years was significant (P < .05).
Conclusions: Biologic behavior and prognosis for bronchial carcinoid tumors are
better than for other lung cancers. Surgical treatment requires radical excision and
lymph node sampling. Survival and long-term outcome are significantly related to
the histologic type, nodal status, and pathologic stage.
Bronchial carcinoid tumors are rare, constituting less than 2% of allpulmonary neoplasms1; 90% of them are confined to the bronchusand only 10% have regional lymph node involvement.2
The tumors occur at any age, have the same incidence in both sexes, and are
characterized by mainly slow endobronchial growth.3,4 Many patients are free of
symptoms, the tumor often being an incidental radiologic finding. Smoking seems
to predispose to the development of these tumors, as it does to the development of
bronchial carcinoma.5-7
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In the recent classification of lung tumors by the World
Health Organization (WHO) and International Association
for the Study of Lung Cancer (IASLC), bronchial carci-
noids are considered part of the neuroendocrine tumor spec-
trum (typical carcinoid, atypical carcinoid, large cell
neuroendocrine carcinoma, and small cell carcinoma), and
typical and atypical carcinoids are grouped together.8 This
is the direct consequence of the fact that typical and atypi-
cal carcinoid tumors are more closely related clinically than
other neuroendocrine tumors and share similar biologic
markers.9
Patients and Methods
We retrospectively reviewed our experience with the management
of both typical and atypical carcinoids to analyze recurrence rates,
survival, and factors that might influence these variables.
Between 1977 and 1999, 126 patients with a final histologic
diagnosis of bronchial carcinoid tumor were assessed for surgery;
in 81 of them, diagnosis and treatment were accomplished during
the past 11 years. Evaluation comprised history and physical
examination, posteroanterior and lateral chest radiographs, and
computed tomographic (CT) scans of the chest and upper
abdomen (including liver and adrenal glands). Bone scintiscans
and brain CT scans were performed in cases of bone pain or neu-
rologic symptoms or signs. Performance status was assessed by
the Karnofsky scale.10 Pulmonary function tests including circula-
tion of single breath diffusing capacity for carbon monoxide were
performed routinely.
All patients had a preoperative examination with a fiberoptic
bronchoscope, and in some cases endoscopic biopsy was per-
formed. Fine-needle aspiration biopsy was performed in peripher-
ally located tumors. At surgery, all specimens resected, including
hilar and mediastinal lymph nodes, were sent for histologic exam-
ination; tumors were classified according to the current
WHO/IASLC criteria for neuroendocrine tumors.8 Typical carci-
noids are defined as tumors greater than 5 mm in diameter, with
carcinoid morphology and less than 2 mitoses per 2 mm2, and
lacking necrosis. Tumors with a mitosis rate of 2 or more but less
than 10 per 2 mm2, with or without necrosis, were classified as
atypical.8-11
Patients were followed up for periods ranging from 6 to 282
months (mean 99 ± 73 months). We analyzed the influence of
tumor site, carcinoid morphology, lymph node involvement, and
the extent of resection on the outcome of surgery.
Results
Clinical Presentation
The group comprised 72 (57%) male and 54 (43%) female
patients; age at presentation ranged from 11 to 77 years
(mean 47 ± 16 years). Patients with atypical carcinoid were,
on average, 9.5 years older at presentation than those with
typical subtype (mean 55 vs 45.5 years, respectively; P <
.05). Symptoms were present in 65 (52%) patients: hemop-
tysis (n = 27), cough (n = 26), recurrent pulmonary infec-
tion (n = 21), fever (n = 15), chest discomfort and chest pain
(n = 14), wheezing (n = 11), and dyspnea (n = 9). Eighteen
(14.2%) patients had been treated for asthma for up to 3
years before the discovery of the tumor. Sixty-one (47%)
patients were asymptomatic at presentation.
Investigations
All patients underwent chest radiographs, chest CT scans,
and preoperative examination with a fiberoptic broncho-
scope. The tumors could be visualized at bronchoscopy in
103 patients, and these were classified as central tumors; the
other 23 tumors were classified as peripheral tumors.
Localization of the Tumor
The tumor was in the right lung in 77 (61%) patients and in
the left lung in 49. The 103 (82%) tumors that were cen-
trally located arose in the following sites: right main
bronchus, 5; left main bronchus, 11; intermediate bronchus,
20; middle lobe bronchus, 9; right upper lobe bronchus, 15;
right inferior lobe bronchus, 16; left upper lobe bronchus,
12; and inferior left bronchus, 15. The other 23 tumors were
peripherally located.
Operations included 15 pneumonectomies (9 of them
performed before the 1990s), 64 standard lobectomies (14
right superior, 9 middle, 16 right inferior, 11 left superior,
14 left inferior), 4 sleeve lobectomies (1 right superior,
2 middle, 1 left superior), 17 bilobectomies, 3 bronchial
sleeve resections, 3 segmentectomies, and 16 wedge
resections.
Pathology
In 70 patients of 82 with a definitive diagnosis of typical
carcinoid, preoperative bronchoscopy allowed the direct
vision of the centrally located tumor. Endoscopic biopsy
was carried out in 47 cases to assess the histologic diagno-
sis: 26 were considered typical carcinoid, 2 atypical carci-
noid, 9 non–small cell lung cancer, and 10 were
nondiagnostic. Nine patients who had non–small cell lung
cancer according to preoperative bronchoscopic biopsy
(before the 1990s) were subjected to pneumonectomy. The
definitive diagnosis of typical carcinoids retrospectively
indicated that sleeve resections of the left main stem
bronchus could have been performed in 6 patients and of
the right main stem bronchus in 3 patients.
Preoperative bronchoscopic biopsy tissue was available
in 28 of 44 patients with a definitive diagnosis of atypical
carcinoid: the specimens were interpreted as showing atypi-
cal carcinoid in 14 patients, typical carcinoid in 8, non–small
cell lung cancer in 2, and were nondiagnostic in 4 patients.
Fine-needle aspiration biopsy was carried out in 9 of 23
patients with peripherally located tumors. Correct diagnosis
with reference to the subtype of neuroendocrine tumor was
obtained for 50% of typical carcinoids and for 66% of atyp-
ical ones: the remaining cases were misinterpreted. All pre-
operative specimens were revised after the definitive
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diagnosis, and in each case the cause of the incorrect diag-
nosis was found to be a misinterpretation of the cellular
pleomorphism. Postoperative staging was complete for 113
of 126 patients (13 patients did not undergo lymph nodal
sampling). Seventy-five (65%) of 113 tumors were consid-
ered typical carcinoids, with 6 (8%) showing lymph node
localization (2 in an N1 and 4 in an N2 position). Because
this is a relatively high percentage for typical carcinoids,
these cases were resubmitted to our pathologists’ evaluation,
and the possibility that these were atypical carcinoids was
excluded (every case demonstrated less than 2 mitotic fig-
ures per high-power field). In no case were the lymph nodes
contiguous with the primary mass. Each N1 cases had hilar
lymph node metastases associated with upper lobe tumors.
N2 cases had subcarinal lymph node metastases related to 3
inferior lobe tumors and 1 middle lobe tumor. 
Fourteen (36.8%) of 38 patients with atypical carcinoid
tumors had nodal deposits, 7 in N1 nodes and 7 with N2 dis-
ease. In each case of N2 disease the diagnosis was made
postoperatively, so that only adjuvant radiation therapy was
administered.
Stage was more advanced among patients with atypical
histologic subtype regardless of the means of categorization
(P < .05). Relative stages for typical and atypical carci-
noids, according to pathologic evaluation of the operative
samples, are shown in Tables 1, 2, 3, and 4. Typical subtype
was stage I in 70 and more advanced (stage II-IV) in 5
patients, whereas atypical subtype was stage I in 20 and
more advanced in 18 patients (P < .05). 
Follow-up was complete until death or within at most 6
months of analysis in all patients with complete staging: 113
(89.8%) of 126 patients. The mean follow-up was 99 ± 73
months (median 84 months, range 6-282 months). Recurrent
cancer developed in 4 (5.5%) of 72 patients with typical and
8 (19.5%) of 41 with atypical subtype (P < .05). Four patients
had intrathoracic recurrence after resection of atypical tumor.
The disease recurred after a median of 3.5 years (range 2-5.5
years). Because reoperation was not feasible (poor pul-
monary function tests in 3 patients and advanced age in 1
patient), these 4 patients were subjected to chemotherapy and
radiation therapy. The median survival for these patients was
3 years (range 2.5-5 years). Eight patients with recurrent
atypical carcinoid had bone and brain metastases, associated
with intrathoracic recurrence in 1, bone metastases in 1, and
liver metastases in 6 patients, a median of 2.5 years (range
1.5-4 years) after the first operation. Five patients (affected
by liver or bone metastases) were subjected to octreotide or
chemotherapy. The median survival after diagnosis of the
recurrent disease was 2 years (range 1.5-3 years). All patients
with recurrent disease died. The incidence of tumor-related
deaths is 12 (10.6%) of 113 patients.
Overall survival at 15 years is 74% (Figure 1). A multi-
variate Cox proportional hazards analysis of survival was
performed with the covariates histologic subtype (Figure 2)
and nodal status (Figure 3).
Discussion
Bronchial carcinoids have gained importance for thoracic
surgeons, in particular whether to regard them as malignant
or benign tumors.3 The WHO/IASLC classification8
includes typical and atypical carcinoids in the spectrum of
neuroendocrine tumors but groups them separately from
TABLE 2. Overall long-term survival of patients with
bronchial carcinoids
Duration of survival
5 years 89%
10 years 79%
15 years 74%
Mean 8.3 ± 6.14 years (range 0-23 years).
TABLE 1. Typical and atypical bronchial carcinoids
subdivided by pathologic staging
Typical Atypical
Stage I 70 20
Stage II 2 4
Stage III 3 12
Stage IV 0 2
Total 75 38
TABLE 4. Long-term survival related to the nodal status
Duration of survival N+ N–
5 years 85% 92%
10 years 52% 87%
15 years 52% 80%
Log-rank test: P = .021; Cox test: P = .011.
TABLE 3. Long-term survival related to the histologic
subtype
Duration of survival Typical carcinoid Atypical carcinoid
5 years 97% 77%
10 years 93% 52%
15 years 84% 52%
Log-rank test: P = .0004; Cox test: P = .0014.
306 The Journal of Thoracic and Cardiovascular Surgery • February 2002
General Thoracic Surgery Filosso et al
ED
ITO
RIA
L
CH
D
G
TS
G
TS
ET
CSP
TX
large cell neuroendocrine carcinoma and small cell lung
carcinoma on the basis of closer histologic and biologic
interrelationships.6,11 They are low-grade malignant
tumors, which can be locally invasive or spread to lymph
nodes, but distant metastases are rare.
The prevalence of these tumors is almost equal in male
and female patients.12 The mean age of our patients at pre-
sentation was 47 ± 16 years (range 11-77 years), which is in
line with other reports.4,13,14 As mentioned by El Jamal and
colleagues,13 patients having atypical carcinoid tumors are
significantly older at presentation than are patients with typ-
ical tumors. 
The influence of smoking on the pathogenesis of carci-
noid tumors is still debated. Two thirds of patients were
Figure 1. Overall long-term survival.
Figure 2. Cumulative proportion surviving (Kaplan-Meier). Long-term survival related to histologic subtype.
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smokers or ex-smokers, as some authors mentioned.7 We
and El Jamal’s group13 noted that the mean age at the diag-
nosis of atypical carcinoid is significantly higher than that
of patients affected by typical carcinoid and is similar to
that of patients with lung carcinoma that is related to ciga-
rette smoking. Detection of a bronchial carcinoid may fol-
low a variety of pulmonary symptoms, or the tumors may
be found on a routine chest radiograph. 
Bronchoscopy plays a big role in the diagnosis of carci-
noids: in the majority of cases the tumor is centrally located
and visible at endoscopic evaluation, as other authors have
described.13,15 Some authors found bleeding to occur in two
thirds of their patients and some advise against biopsy when
carcinoid is suspected6,16,17; other authors disagreed, main-
taining that bronchoscopic biopsy significantly increases
the diagnostic yield without adding morbidity.18 In our
experience, no troublesome bleeding was reported after
endoscopic biopsy. The main problem was the difficulty in
obtaining an accurate diagnosis in carcinoid tumors.
Endoscopic sampling suggested the diagnosis of carcinoid
in 67% of cases, and the correct subtype of the tumor was
detected in 53%. Of 75 bronchoscopic biopsies, 35 were not
diagnostic or yielded an incorrect diagnosis: in 11 of the 35,
non–small cell lung cancer was preoperatively diagnosed
and then pneumonectomy was performed. Nine of 11 were
postoperatively diagnosed as typical carcinoids, and pneu-
monectomy clearly was unnecessary inasmuch as all
patients could have been successfully treated by a bronchial
sleeve resection. The accuracy of fine-needle aspiration
biopsy suggests the correct diagnosis in peripherally
located tumors was about 55%. It is not surprising that the
pathologist should have difficulty in differentiating typical
from atypical carcinoid tumors, because such features as
increased mitotic rate and necrosis may not be present in a
biopsy sample.
Most tumors are localized and the likelihood of local
recurrence after resection is small. This is attested to by a
15-year survival of 80% in patients with localized disease
and 52% in patients with regionally advanced or metastatic
disease in our study.
The assessment of the biologic behavior of bronchial
carcinoid tumors is not always accurate. Atypical carcinoid
tumors present more often at a more advanced stage, are
more likely to recur, and are associated with lower 5- and
10-year survivals than are typical carcinoids. These findings
reveal the need for more accurate differentiation between
histologic subtypes. Strict application of classification cri-
teria and perhaps revision of classification criteria are
mandatory to allow distinction between typical and atypical
subtypes that could influence surgical management.
During recent years, immunohistochemical analysis,
measurement of DNA ploidy, and assessment of chromoso-
mal deletions (11q, 3p) have been proposed, but none of
these has been shown to be useful preoperatively or intra-
operatively to guide selection of surgical management.19-21
Actually, the only reliable factors for assessing aggressive-
ness are the tumor stage and its histologic subtype. 
Preoperative radiologic evaluation and histologic type
are mandatory in selecting the extent of surgical resection.
Newer modalities for staging bronchial carcinoid tumors
Figure 3. Cumulative proportion surviving (Kaplan-Meier). Long-term survival related to nodal involvement.
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that have recently been introduced include positron emis-
sion tomography and octreotide scintigraphy. Positron
emission tomographic imaging of bronchial carcinoid
tumors demonstrates lower uptake than non–small cell lung
cancers, suggesting that the process is benign and that stag-
ing of regional lymph nodes might be unreliable.22
Scintigraphy with 111In-octreotide has demonstrated reli-
able uptake in primary tumors and the ability to detect early
recurrences and metastases even in asymptomatic patients,
suggesting that it might be a useful tool for routine staging
in the future.23 At present, however, decisions regarding
appropriate therapy for patients with bronchial carcinoid
tumors are made on the basis of histologic findings, clinical
staging with bronchoscopy and CT, and in some instances
intraoperative lymph node staging.
The current surgical management of bronchial carci-
noids is influenced by the recurrence rates and survival pat-
terns we and others have observed.1,6,9,13,14,16-18,24,25 In
patients with centrally located typical carcinoid tumor of
the lung, we think that bronchial sleeve resection or sleeve
lobectomy should be considered, when possible, because
local recurrence is rare and survival is excellent. Despite the
low local recurrence rate, early-stage typical carcinoids
should be considered to be low-malignancy neoplasms and
should be managed by an anatomic resection when periph-
erally located (lobectomy if pulmonary function tests are
adequate or segmentectomy in other cases) to secure the
least risk of recurrence. On the other hand, local recurrence
rate and long-term survival are both unfavorably affected by
the finding of atypical subtype: if this histologic subtype is
identified, a more extensive surgical approach (such as
lobectomy or pneumonectomy) associated with lymph node
dissection is mandatory.
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Discussion
Dr Mark S. Allen (Rochester, Minn). Carcinoid tumors are a
unique type of malignant pulmonary disease. They are rare, com-
prising less than 5% of all primary pulmonary neoplasms. Most of
them arise in the bronchial airways. Usually they are classified as
a typical carcinoid, a less virulent variety, versus an atypical vari-
ety, a more virulent type. However, both types of carcinoids are
malignant and should be treated as such. This series represents a
large number of patients who have undergone surgical resection
for bronchial carcinoid tumors. This series is among the largest in
the literature and shows characteristics that others have seen. The
male/female distribution is nearly equal, no clear association with
cigarette smoking is identified, and long-term survival after com-
plete resection is relatively good. 
Since pulmonary carcinoids are usually located in the central
bronchial tree, they are readily visualized by bronchoscopy. Dr
Filosso, you say that you performed a preoperative bronchoscopic
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examination in all patients, but I am puzzled about why you
obtained biopsy specimens in 98 (77%) of the 126 patients. I do
not think a biopsy is necessary in the majority of patients with a
bronchial carcinoid once the bronchoscopic examination has dis-
closed a resectable lesion. The pathologic distinction between typ-
ical or atypical is not really very important, because regardless of
what the pathologic examination shows, surgical resection is the
proper management. Furthermore, as you have shown, the pathol-
ogy results from the biopsy are often misleading. Do you think
biopsies are appropriate in all bronchial tumors, and did you have
any difficulty with bleeding in any of the 98 biopsies? 
My second question relates to the operation you performed on
your patients. You stated that 82% of the patients had a centrally
located lesion. Eleven patients had a left main stem bronchial
lesion, 5 lesions were in the right main stem bronchus, and 20
were in the bronchus intermedius. Yet, only 7 (5%) of the 126
patients had a sleeve resection, and 15 (12%) patients required a
pneumonectomy. Do you think that sleeve resection is not a good
operation for a bronchial carcinoid? Why was the number of
sleeve resections not higher? I think that a lung-conserving opera-
tion is best for a patient with a carcinoid if it is feasible.
Finally, in your analysis of the outcome, the only factors that
influenced survival were the histologic subtype and nodal disease.
Did you examine any molecular markers, such as DNA ploidy, p53
levels, or chromosome deletions to determine whether these
affected survival? 
Dr William H. Warren (Chicago, Ill). The literature on low-
grade neuroendocrine tumors has been needlessly confused by
persisting in lumping typical and “atypical” carcinoids as if they
were one entity with two different minor subtypes. Thus, when we
find their prognoses are different, we conclude that they should be
distinguished again. These are two separate tumors, and I think it
is time we start discussing them as such from the beginning. 
I have two questions: First, 5 patients with typical bronchial
carcinoids were found to have nodal metastases. Did that influence
survival? Second, if nodal metastases were found, would you con-
sider giving chemotherapy, and, if so, what type? In our series of
over 150 typical bronchial carcinoids at Rush Presbyterian–St
Luke’s Medical Center, we have found 7 patients with N1 or N2
nodal metastases, but this has not seemed to influence the progno-
sis without any form of adjuvant therapy.
Dr Filosso. I agree with Dr Allen about the opportunity to per-
form sleeve lobectomies in carcinoid tumors, when possible.
Pneumonectomies and bilobectomies were performed, in our
series, when the lung was destroyed by long-term infections. In
fact, some of our patients were treated for asthma for 2 or 3 years
before a bronchial carcinoid was diagnosed. In the last period of
our experience, the number of pneumonectomies and bilobec-
tomies was dramatically reduced thanks to correct preoperative
diagnoses. We performed bronchoscopy in all patients with a cen-
trally located tumor, and we had no experience of troublesome
bleeding during these procedures.
The possibility to use molecular markers, such as p53 or Ki67,
could help us to determine the outcome of neuroendocrine
tumors, but at the department of pathology of our hospital these
procedures are not yet routinely used. I have, on the contrary,
an interesting experience with 111In-diethylenetriamine pentaac-
etate-pentetreotide scintigraphy (OctreoScan), used in both the
preoperative and the follow-up studies. Mediastinal lymph node
metastases and recurrences of resected carcinoids were correctly
diagnosed by this procedure, and in selected cases, I treated
recurrences (not resectable) or distant metastases with “cold”
octreotide, with success.
To Dr Warren: We had not observed a significant decrease in
long-term survival of N2 typical carcinoids. We do not perform
chemotherapy in these patients: we prefer radiation therapy.
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